Humira Biosimilar, Hulio, Will Soon Be Available to AS, Other Patients in Europe
The European Commission (EU) has granted marketing authorization for Hulio, a biosimilar to Humira, for the treatment of a number of chronic inflammatory diseases including ankylosing spondylitis. According to the EC’s decision, Hulio will be available in the 28 EU member countries and three European Economic Area member states —…